Abstract

To evaluate the effects of Lactobacillus acidophilus tablets based on quadruple therapy on intestinal flora and inflammatory response in patients with Helicobacter pylori-infected chronic atrophic gastritis is the objective of the study. The clinical data of Helicobacter pylori-infected patients with Helicobacter pylori-infected chronic atrophic gastritis were analyzed retrospectively and 90 patients who met the criteria of inclusion and exclusion were selected as subjects. The control group was treated with conventional quadruple therapy and the observation group was treated with compound Lactobacillus acidophilus tablets combined with quadruple therapy. The intestinal flora and inflammation of the patients were compared. The efficacy of 82 % (41/50) and 96 % (p<0.05) were significantly higher in the post-treatment observation group than in the control group; the area of gastric lesion (0.85±0.17) was significantly lower than in the control group (p<0.05) and the digestive system symptoms score (3.23±1.13) was significantly lower than in the control group (6.67 %). Gastrointestinal function score (4.63±1.39) and Helicobacter pylori eradication rate (47/50) were significantly higher (94 %) in the observation group than in the control group, p<0.05; tumor necrosis factor alpha, (23.39±6.20 µg/ml) and interleukin-6 (15.39±6.41 µg/ml) were significantly lower than that in the control group and gastrin level (1.78±0.19 nmol/l) was significantly higher. Compound Lactobacillus acidophilus tablets based on quadruple therapy for the treatment of Helicobacter pylori-infected chronic atrophic gastritis can well eradicate Helicobacter pylori, control intestinal inflammation, improve intestinal flora and reduce clinical symptoms and signs of patients.